Why kidney damage keeps progressing
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
The hardest thing to explain about CKD is why it continues after the original cause has been treated. The answer is that nephron loss itself causes further nephron loss.
Understanding that cycle explains why the main treatments work by reducing pressure inside the filter rather than by repairing anything.
Related pages: Chronic kidney disease
The bottom line
- Surviving nephrons compensate by filtering harder, which damages them over time.
- High pressure inside the glomerulus drives scarring, called glomerulosclerosis.
- Protein leaking into the tubules is itself toxic to them, so proteinuria drives damage as well as marking it.
- ACE inhibitors and ARBs lower pressure inside the glomerulus specifically, beyond their systemic blood pressure effect.
- SGLT2 inhibitors reduce hyperfiltration by a different route and slow progression in trials.
- Whether scarring can ever be reversed rather than slowed.
- Why progression rates differ so much between individuals with similar damage.
- How best to combine the available anti-progression treatments.
The story, step by step
What the evidence labels mean
Fewer nephrons, working harder
What happens
An adaptation that becomes the problem.
What the research shows
- When nephrons are lost, the remaining ones increase their filtration rate and enlarge, a process called compensatory hyperfiltration and hypertrophy.
- This keeps overall eGFR near normal for a long time, which is part of why early CKD is invisible on a blood test.
- Sustaining it requires higher pressure inside each remaining glomerulus, called intraglomerular hypertension.
- Sustained high pressure injures the capillary tuft and the podocytes, producing scarring.
- Each scarred nephron is lost, and the survivors compensate further. The cycle continues without the original insult.
- This is why a kidney injury that happened years ago can still be progressing today.
Why it matters
The cycle is the reason CKD is treated as a condition in its own right, not merely as a complication of diabetes or blood pressure.
What's still uncertain
- Why the cycle runs fast in some people and barely at all in others.
- Whether there is a point of no return.
Read more
- KDIGO: CKD evaluation and management guidelineNonprofit
- NIDDK: Chronic kidney diseaseGovernment
- NIDDK: Diabetic kidney diseaseGovernment
Next: The scarring
What glomerulosclerosis is
What happens
Filter replaced by scar.
What the research shows
- Glomerulosclerosis is the replacement of functioning filter tissue with scar. The nephron stops working.
- The tubules and surrounding tissue scar too, called tubulointerstitial fibrosis. The extent of this correlates better with kidney function than the glomerular changes do.
- Scarring is not reversible with current treatment. Treatment aims at preventing further scarring, not at undoing it.
- This is why treatment started early preserves far more function than treatment started late.
- It is also why eGFR rarely improves much after treatment. Stabilising a falling number is a success, even though it does not feel like one.
- Kidney biopsy is sometimes used to establish how much scarring is present and whether an active, treatable process is also going on.
Why it matters
Expecting eGFR to climb back is the most common source of disappointment in CKD care. Holding it steady is the actual goal.
What's still uncertain
- Whether antifibrotic treatments will change this.
- Which patients benefit from biopsy.
Read more
- KDIGO: CKD evaluation and management guidelineNonprofit
- NIDDK: Chronic kidney diseaseGovernment
- MedlinePlus: Chronic kidney diseaseGovernment
Next: Protein as a cause
Not just a marker
What happens
Leaked albumin damages the tubules.
What the research shows
- Albumin that escapes the filter is taken up by the tubule cells downstream.
- In quantity, this triggers inflammation and fibrosis in the tubules, accelerating the loss of the nephron.
- So proteinuria is both a sign of damage and a driver of further damage, which is unusual and clinically useful.
- It means that reducing protein leak is a treatment target in itself, not merely a way of watching the disease.
- In trials, treatments that reduce albuminuria tend to slow the fall in eGFR, supporting the causal link.
- A reduction in urine albumin after starting treatment is therefore a genuinely good sign, not just a better number.
Why it matters
This is why the urine test is repeated during treatment and not only at diagnosis. It is one of the few things in CKD that responds visibly.
What's still uncertain
- Whether albuminuria reduction is a valid surrogate endpoint for trials.
- How much reduction is enough.
Read more
- KDIGO: CKD evaluation and management guidelineNonprofit
- NIDDK: Tests and diagnosis of chronic kidney diseaseGovernment
- NIH: SGLT2 inhibitor trials in chronic kidney diseaseGovernment
Next: Breaking the cycle
Where treatment acts
What happens
Lower the pressure inside the filter.
What the research shows
- ACE inhibitors and ARBs dilate the vessel leaving the glomerulus, which lowers pressure inside it specifically.
- This produces a small, expected drop in eGFR when treatment starts, typically up to around 30 percent. That drop is a sign the drug is working, not a sign of harm, and it stabilises.
- SGLT2 inhibitors restore a feedback signal at the start of the tubule that tightens the vessel entering the glomerulus, again lowering internal pressure. They also cause an initial eGFR dip that then flattens the long-term slope.
- Trials of SGLT2 inhibitors in CKD, with and without diabetes, showed reduced progression to kidney failure and reduced cardiovascular events.
- Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces progression in CKD with type 2 diabetes through anti-inflammatory and antifibrotic effects.
- Blood pressure control more generally, with a target often below 130/80, reduces the pressure load reaching the glomerulus.
Why it matters
The initial eGFR dip is the single most misunderstood thing in CKD treatment. People stop effective drugs because of it, which is exactly the wrong response.
What's still uncertain
- How best to combine ACE inhibitor, SGLT2 inhibitor and finerenone.
- Whether antifibrotic drugs will add further benefit.